Silver Book Fact

Because the resource use and direct cost of glaucoma treatment and management increases as the disease severity worsens– from an average $623 per early-stage patient to $2,511 per late-stage patient– a glaucoma treatment that delays the disease progression could significantly reduce its economic burden.

Lee, Paul P., John G. Walt, John L. Doyle, Sameer V. Kotak, Stacy J. Evans, Donald L. Budenz, Philip P. Chen, Anne L. Coleman, Robert M. Feldman, Henry D. Jampel, L. Jay Katz, Richard P. Mills, Jonathan S. Myers, Robert J. Noecker, et al. A Multicenter, Retrospective Pilot Study of Resource Use and Costs Associated with Severity of Disease in Glaucoma. Archives of Ophthalmology. 2006; 124(1): 12-9. http://archopht.ama-assn.org/cgi/content/abstract/124/1/12

Reference

Title
A Multicenter, Retrospective Pilot Study of Resource Use and Costs Associated with Severity of Disease in Glaucoma
Publication
Archives of Ophthalmology
Publication Date
2006
Authors
Lee, Paul P., John G. Walt, John L. Doyle, Sameer V. Kotak, Stacy J. Evans, Donald L. Budenz, Philip P. Chen, Anne L. Coleman, Robert M. Feldman, Henry D. Jampel, L. Jay Katz, Richard P. Mills, Jonathan S. Myers, Robert J. Noecker, et al
Volume & Issue
Volume 124, Issue 1
Pages
12-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Intensive Glycemic Control in People with Diabetes
    Intensive glycemic control in diabetics reduced their: Adjusted mean risk of DR by 76% Risk of progression by 54% Rates of laser surgery by 56% Risk of DME by 23%    
  • Economics of DR Treatment
    Laser treatment plus a VEGF inhibitor achieved an incremental cost-effectiveness ratio of $12,410 per quality adjusted life year in patients with DME.  
  • Gene transfer process treatment for diabetic retinopathy
    A gene transfer process that produces a VEGF receptor prevents retinal vascular permeability (RVP) associated with diabetes that could have value in treating diabetic retinopathy.  
  • The ACCORD Eye Study found that intensive glycemia control–compared with standard blood sugar control–in high risk type 2 diabetics, decreased progression of diabetic retinopathy by around 1/3 over 4 years–from…  
  • Anti-VEGF Letter Improvement
    An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.